A Phase I/Expansion Study of Dasatinib

NCT00598091 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

OTHER

Sponsor class

Stopped Low accrual, unable to meet endpoint in timely manner

Conditions

Refractory Solid Tumors
Pancreatic Adenocarcinoma

Interventions

DRUG: gemcitabine
DRUG: dasatinib
DRUG: gemcitabine
DRUG: dasatinib

Sponsor

Duke University

Collaborators

[object Object]